Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing

被引:82
作者
Dolton, Michael J. [1 ,2 ]
Mikus, Gerd [3 ]
Weiss, Johanna [3 ]
Ray, John E. [4 ]
McLachlan, Andrew J. [1 ,2 ]
机构
[1] Univ Sydney, Fac Pharm, Camperdown, NSW, Australia
[2] Concord Repatriat Gen Hosp, Ctr Educ & Res Ageing, Concord, Australia
[3] Univ Heidelberg Hosp, Heidelberg, Germany
[4] St Vincents Hosp, SydPath, Darlinghurst, NSW 2010, Australia
关键词
antifungals; azoles; CYP2C19; EFFICACY; SAFETY; METABOLISM; GENOTYPE; OBESE;
D O I
10.1093/jac/dku031
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Voriconazole exhibits highly variable, non-linear pharmacokinetics and is associated with a narrow therapeutic range. This study aimed to investigate the population pharmacokinetics of voriconazole in adults, including the effect of CYP2C19 genotype and drug-drug interactions. Non-linear mixed effects modelling (NONMEM) was undertaken of six voriconazole studies in healthy volunteers and patients. Dosing simulations to examine influential covariate effects and voriconazole target attainment (2-5 mg/L) stratified by CYP2C19 phenotype were performed. We analysed 3352 voriconazole concentration measurements from 240 participants. A two-compartment pharmacokinetic model with first-order oral absorption with lag time and Michaelis-Menten elimination best described voriconazole pharmacokinetics. Participants with one or more CYP2C19 loss-of-function (LoF) alleles had a 41.2% lower V-max for voriconazole. Co-administration of phenytoin or rifampicin, St John's wort or glucocorticoids significantly increased voriconazole elimination. Among patients receiving 200 mg of voriconazole twice daily, predicted trough concentrations on day 7 were < 2 mg/L for oral and intravenous regimens for 72% and 63% of patients without CYP2C19 LoF alleles, respectively, with 49% and 35% below this threshold with 300 mg twice daily dosing. Conversely, these regimens resulted in 29%, 39%, 57% and 77% of patients with CYP2C19 LoF alleles with voriconazole trough concentrations a parts per thousand yen5 mg/L. Current dosing regimens for voriconazole result in subtherapeutic exposure in many patients without CYP2C19 LoF alleles, suggesting the need for higher doses, whereas these regimens result in supratherapeutic exposure in a high proportion of patients with reduced CYP2C19 activity. These findings support the essential role of therapeutic drug monitoring in ensuring efficacious and safe voriconazole exposure.
引用
收藏
页码:1633 / 1641
页数:9
相关论文
共 37 条
[1]   Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models [J].
Bergstrand, Martin ;
Hooker, Andrew C. ;
Wallin, Johan E. ;
Karlsson, Mats O. .
AAPS JOURNAL, 2011, 13 (02) :143-151
[2]  
Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P1, DOI 10.1007/978-1-4419-9485-1
[3]   Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter [J].
Chen, YP ;
Ferguson, SS ;
Negishi, M ;
Goldstein, JA .
MOLECULAR PHARMACOLOGY, 2003, 64 (02) :316-324
[4]   Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids [J].
Czock, D ;
Keller, F ;
Rasche, FM ;
Häussler, U .
CLINICAL PHARMACOKINETICS, 2005, 44 (01) :61-98
[5]   Voriconazole Serum Concentrations in Obese and Overweight Immunocompromised Patients: A Retrospective Review [J].
Davies-Vorbrodt, Samantha ;
Ito, James I. ;
Tegtmeier, Bernard R. ;
Dadwal, Sanjeet S. ;
Kriengkauykiat, Jane .
PHARMACOTHERAPY, 2013, 33 (01) :22-30
[6]   Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring [J].
Dolton, Michael J. ;
Ray, John E. ;
Chen, Sharon C. -A. ;
Ng, Kingsley ;
Pont, Lisa G. ;
McLachlan, Andrew J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (09) :4793-4799
[7]   Clinical importance of the CYP2C19*17 variant allele for voriconazole [J].
Dolton, Michael J. ;
McLachlan, Andrew J. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (01) :137-138
[8]  
FABER OK, 1974, ACTA PHARMACOL TOX, V35, P195
[9]  
FDA, 2013, CTR DRUG EV RES CLIN
[10]   Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults [J].
Friberg, Lena E. ;
Ravva, Patanjali ;
Karlsson, Mats O. ;
Liu, Ping .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) :3032-3042